Cardiovascular diseases have become a major clinical burden globally. Heart failure is one
of the diseases that commonly emanates from progressive uncontrolled hypertension. This …

Sacubitril/valsartan (S/V) is a pharmaceutical strategy that increases natriuretic peptide
levels by inhibiting neprilysin and regulating the renin-angiotensin-aldosterone pathway …

Methods In this retrospective, multicenter cohort study, 600 patients with HF with reduced left-
ventricular ejection fraction (LVEF< 40%) with≥ 1 sacubitril/valsartan prescription were …

Fibrosis is present in an important proportion of myocardial disorders. Injury activates
cardiac fibroblasts, which deposit excess extracellular matrix, increasing tissue stiffness …

Background Some, but not all, recent studies have shown that renal denervation (RDN) can
improve cardiac function and exercise tolerance in people who have heart failure with …

Heart failure (HF) is a growing health concern in aging societies worldwide.
Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The …

Heart failure (HF) is a condition in which the heart is unable to pump enough blood to meet
the body's needs for blood and oxygen. Thus, HF is a grave disease with high morbidity and …

Purpose This study was to investigate the association between the use of Sodium-glucose
Cotransporter-2 inhibitors (SGLT2i) or angiotensin receptor-neprilysin inhibitor (ARNI; ie …

This Korean nationwide, multicenter, noninterventional, prospective cohort study aimed to
analyze physician adherence to guideline-recommended therapy for heart failure (HF) with …

Heart failure with preserved ejection fraction (HFpEF) is now the most common form of heart
failure (HF) and accounts for about half the HF cases. 1 It is a growing burden to the health …